AU2002228317A1 - Benz-1,3-azole derivatives and their uses as heparanase inhibitors - Google Patents

Benz-1,3-azole derivatives and their uses as heparanase inhibitors

Info

Publication number
AU2002228317A1
AU2002228317A1 AU2002228317A AU2002228317A AU2002228317A1 AU 2002228317 A1 AU2002228317 A1 AU 2002228317A1 AU 2002228317 A AU2002228317 A AU 2002228317A AU 2002228317 A AU2002228317 A AU 2002228317A AU 2002228317 A1 AU2002228317 A1 AU 2002228317A1
Authority
AU
Australia
Prior art keywords
benz
azole derivatives
heparanase inhibitors
heparanase
inhibitors
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228317A
Inventor
Maty Ayal-Hershkovitz
Ofra Levy
Daphna Miron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Insight Strategy and Marketing Ltd
Original Assignee
Insight Strategy and Marketing Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insight Strategy and Marketing Ltd filed Critical Insight Strategy and Marketing Ltd
Publication of AU2002228317A1 publication Critical patent/AU2002228317A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
AU2002228317A 2001-01-29 2002-01-29 Benz-1,3-azole derivatives and their uses as heparanase inhibitors Abandoned AU2002228317A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26430601P 2001-01-29 2001-01-29
US60/264,306 2001-01-29
PCT/IL2002/000081 WO2002060374A2 (en) 2001-01-29 2002-01-29 Benz-1,3-azole derivatives and their uses as heparanase inhibitors

Publications (1)

Publication Number Publication Date
AU2002228317A1 true AU2002228317A1 (en) 2002-08-12

Family

ID=23005454

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228317A Abandoned AU2002228317A1 (en) 2001-01-29 2002-01-29 Benz-1,3-azole derivatives and their uses as heparanase inhibitors

Country Status (2)

Country Link
AU (1) AU2002228317A1 (en)
WO (1) WO2002060374A2 (en)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1553089B1 (en) 2002-07-30 2009-09-30 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
CA2496633A1 (en) * 2002-08-30 2004-04-29 Bf Research Institute, Inc. Diagnostic probes and remedies for diseases with accumulation of prion protein, and stains for prion protein
WO2004046122A2 (en) * 2002-11-16 2004-06-03 Oxford Glycosciences (Uk) Ltd Benzoxazole, benzthiazole and benzimidazole acid derivatives and their use as heparanase inhibitors
GB0226822D0 (en) * 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
CA2546601A1 (en) 2003-11-19 2005-06-09 Metabasis Therapeutics, Inc. Novel phosphorus-containing thyromimetics
US7781478B2 (en) 2004-07-14 2010-08-24 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7772271B2 (en) 2004-07-14 2010-08-10 Ptc Therapeutics, Inc. Methods for treating hepatitis C
US7868037B2 (en) 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
WO2006019831A1 (en) 2004-07-14 2006-02-23 Ptc Therapeutics, Inc. Methods for treating hepatitis c
JP2008507518A (en) 2004-07-22 2008-03-13 ピーティーシー セラピューティクス，インコーポレーテッド Thienopyridine for treating hepatitis C
EP1898926A2 (en) 2005-05-26 2008-03-19 Metabasis Therapeutics, Inc. Thyromimetics for the treatment of fatty liver diseases
EP2086553A4 (en) * 2006-10-20 2010-12-29 Univ Australian Inhibition of degradation of extracellular matrix
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
GB0821913D0 (en) * 2008-12-02 2009-01-07 Price & Co Antibacterial compounds
CN101735152A (en) * 2009-12-18 2010-06-16 长沙理工大学 2,2'-(1,4-phenylene)bi(benzimidazole-5-carboxylic acid) and preparation method thereof
US8686048B2 (en) * 2010-05-06 2014-04-01 Rhizen Pharmaceuticals Sa Immunomodulator and anti-inflammatory compounds
EP3011960B1 (en) 2010-06-01 2020-04-15 Summit Therapeutics plc Compounds for the treatment of clostridium difficile-associated disease
CA3044059A1 (en) 2016-11-21 2018-05-24 Viking Therapeutics, Inc. Method of treating glycogen storage disease
US11787783B2 (en) 2016-12-13 2023-10-17 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
CA3046997A1 (en) 2016-12-13 2018-06-21 Beta Therapeutics Pty Ltd Heparanase inhibitors and use thereof
EP3381906A1 (en) * 2017-03-27 2018-10-03 Leadiant Biosciences SA Compounds for use as heparanase inhibitors
EP3381907A1 (en) 2017-03-27 2018-10-03 Leadiant Biosciences SA Symmetrical 2-aminophenyl-benzazolyl-5-acetate compounds and their use as anti-heparanase
EA201992703A1 (en) 2017-06-05 2020-04-15 Вайкинг Терапьютикс, Инк. COMPOSITIONS FOR TREATING FIBROSIS
CA3094167A1 (en) 2018-03-22 2019-09-26 Viking Therapeutics, Inc. Crystalline forms and methods of producing crystalline forms of a compound

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153631A (en) * 1996-10-23 2000-11-28 Zymogenetics, Inc. Compositions and methods for treating bone deficit conditions
US5932600A (en) * 1997-03-14 1999-08-03 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
JP2001226358A (en) * 1999-10-12 2001-08-21 Japan Tobacco Inc Lpl potentiator

Also Published As

Publication number Publication date
WO2002060374A3 (en) 2003-02-27
WO2002060374A2 (en) 2002-08-08

Similar Documents

Publication Publication Date Title
AU2002228316A1 (en) Carbazole derivatives and their uses as heparanase inhibitors
AU2002228317A1 (en) Benz-1,3-azole derivatives and their uses as heparanase inhibitors
AU2003266321A1 (en) Tetrahydropyrimidine-2-one derivatives and their uses
AU2002358700A1 (en) Urea derivatives as vr1- antagonists
AU2002362895A1 (en) 5-carbamoyl-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AU2002367186A1 (en) Urea derivatives
AU2002346929A1 (en) 5-acylamino-1,1-biphenyl-4-carboxamide derivatives and their use as p38 kinase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
ZA200501677B (en) Hydantoin derivatives and their use as TACE inhibitors.
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2002349676A1 (en) 4-oxoquinoline derivatives
AU2003236135A1 (en) Aralkyl-alcohol peiperazine derivatives and their uses as antidepressant
AU2002352444A1 (en) Quinazolinedione derivatives
AU2003301968A1 (en) 4-aminomethyl-1-aryl-cyclohexylamine derivatives
AU2002230057A1 (en) Diphenyl ether derivatives and their uses as heparanase inhibitors
AU2003296564A1 (en) 4-hydroxymethyl-1-aryl-cyclohexylamine derivatives
AU2003278369A1 (en) 3-cyano-quinoline derivatives
AU2002216650A1 (en) Triazine derivatives as lpaat-b inhibitors and uses thereof
AU2003222659A1 (en) 23-o-substituted 5-o-mycaminosyltylonide derivatives
AU2003234131A1 (en) 5-o-mycaminosyltylonide derivatives
AU2002230056A1 (en) Indole derivatives and their uses as heparanase inhibitors
AU2003267169A1 (en) Compounds, compositions and methods
AU2002338989A1 (en) Substituted C-furan-2-yl-methylamine and C-thiophen-2-yl-methylamine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase